Skip to main content
Erschienen in: World Journal of Urology 12/2015

01.12.2015 | Original Article

The effects of statins on benign prostatic hyperplasia in elderly patients with metabolic syndrome

verfasst von: Xiangyu Zhang, Xiaofang Zeng, Lini Dong, Xiaokun Zhao, Xiaobing Qu

Erschienen in: World Journal of Urology | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the effects of simvastatin and atorvastatin in elderly male patients with benign prostatic hyperplasia (BPH) accompanied by metabolic syndrome (MetS).

Methods

Eligible patients aged >60 year with BPH accompanied by MetS were randomly assigned to receive 40 mg of simvastatin daily, 20 mg of atorvastatin daily or placebo (control group) treatment for 12 months. Serum lipids, interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), prostate-specific antigen, prostate volume (PV) and the International Prostate Symptom Score (IPSS) were tested before and after treatment.

Results

The levels of serum total cholesterol (TC), triglycerides, low-density lipoprotein cholesterol, hs-CRP, IL-6 and IPSS was decreased, serum high-density lipoprotein cholesterol (HDL-C) was increased, and PV was reduced in the patients following treatments with statins. The PV of the patients who received simvastatin were reduced more than those of the patients who received atorvastatin. The decrease in PV was more significant in the obesity patients than in the normal weight patients and in the hyperlipidemia patients than in the normal-lipid patients following the statin interventions. The reduction in PV was positively related to the decreases in the levels of TC and IL-6 and to the increase in the level of HDL-C.

Conclusions

Simvastatin and atorvastatin significantly reduced PV, improved lower urinary tract symptoms, and slowed the clinical progression of BPH possibly by lowering cholesterol and anti-inflammatory factors.
Literatur
1.
Zurück zum Zitat Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287(3):356–359CrossRefPubMed Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287(3):356–359CrossRefPubMed
2.
Zurück zum Zitat Pashootan P, Ploussard G, Cocaul A, De Gouvello A, Desgrandchamps F(2014) Association between metabolic syndrome and severity of lower urinary tract symptoms: an observational study in a 4,666 European men cohort. BJU Int 17. doi: 10.1111/bju.12931. [Epub ahead of print] Pashootan P, Ploussard G, Cocaul A, De Gouvello A, Desgrandchamps F(2014) Association between metabolic syndrome and severity of lower urinary tract symptoms: an observational study in a 4,666 European men cohort. BJU Int 17. doi: 10.​1111/​bju.​12931. [Epub ahead of print]
3.
Zurück zum Zitat Park YW, Kim SB, Kwon H, Kang HC, Cho K, Lee KI, Kim YJ, Lee JH (2013) The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome. Urology 82(3):674–679CrossRefPubMed Park YW, Kim SB, Kwon H, Kang HC, Cho K, Lee KI, Kim YJ, Lee JH (2013) The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome. Urology 82(3):674–679CrossRefPubMed
4.
Zurück zum Zitat Zhang X, Zeng X, Liu Y, Dong L, Zhao X, Qu X (2014) Impact of metabolic syndrome on benign prostatic hyperplasia in elderly Chinese men. Urol Int 93(2):214–219CrossRefPubMed Zhang X, Zeng X, Liu Y, Dong L, Zhao X, Qu X (2014) Impact of metabolic syndrome on benign prostatic hyperplasia in elderly Chinese men. Urol Int 93(2):214–219CrossRefPubMed
5.
Zurück zum Zitat Gacci M, Vignozzi L, Sebastianelli A, Salvi M, Giannessi C, De Nunzio C, Tubaro A, Corona G, Rastrelli G, Santi R, Nesi G, Serni S, Carini M, Maggi M (2013) Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer Prostatic Dis 16(1):101–106CrossRefPubMed Gacci M, Vignozzi L, Sebastianelli A, Salvi M, Giannessi C, De Nunzio C, Tubaro A, Corona G, Rastrelli G, Santi R, Nesi G, Serni S, Carini M, Maggi M (2013) Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer Prostatic Dis 16(1):101–106CrossRefPubMed
6.
Zurück zum Zitat Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Weiss N, Goodman P et al (2007) Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol 177(4):1395–1400CrossRefPubMed Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Weiss N, Goodman P et al (2007) Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol 177(4):1395–1400CrossRefPubMed
7.
Zurück zum Zitat Rohrmann S, Smit E, Giovannucci E, Platz EA (2005) Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond) 29(3):310–316CrossRef Rohrmann S, Smit E, Giovannucci E, Platz EA (2005) Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond) 29(3):310–316CrossRef
8.
Zurück zum Zitat Parsons JK, Bergstrom J, Barrett-Connor E (2008) Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int 101(3):313–318CrossRefPubMedPubMedCentral Parsons JK, Bergstrom J, Barrett-Connor E (2008) Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int 101(3):313–318CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F (2009) Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate 69(16):1774–1780CrossRefPubMedPubMedCentral Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F (2009) Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate 69(16):1774–1780CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA (2005) Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate 62(1):27–33CrossRefPubMed Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA (2005) Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate 62(1):27–33CrossRefPubMed
11.
Zurück zum Zitat Zhang X, Shen F, Dong L, Zhao X, Qu X (2013) Influence and pathophysiological mechanisms of simvastatin on prostatic hyperplasia in spontaneously hypertensive rats. Urol Int 91(4):467–473CrossRefPubMed Zhang X, Shen F, Dong L, Zhao X, Qu X (2013) Influence and pathophysiological mechanisms of simvastatin on prostatic hyperplasia in spontaneously hypertensive rats. Urol Int 91(4):467–473CrossRefPubMed
12.
Zurück zum Zitat Solomon KR, Freeman MR (2008) Do the cholesterol-lowering properties of statins affect cancer risk? Trends Endocrinol Metab 19(4):113–121CrossRefPubMed Solomon KR, Freeman MR (2008) Do the cholesterol-lowering properties of statins affect cancer risk? Trends Endocrinol Metab 19(4):113–121CrossRefPubMed
13.
Zurück zum Zitat Ozden C, Ozdal OL, Urgancioglu G et al (2007) The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 51(1):199–206CrossRefPubMed Ozden C, Ozdal OL, Urgancioglu G et al (2007) The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 51(1):199–206CrossRefPubMed
14.
Zurück zum Zitat Hammarsten J, Hogstedt B (2001) Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 39(2):151–158CrossRefPubMed Hammarsten J, Hogstedt B (2001) Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 39(2):151–158CrossRefPubMed
15.
Zurück zum Zitat Mitropoulos D, Ploumidou K, Kyroudi-Voulgari A et al (2003) Hypercholesterol diet alters serum lipid profile and ventral prostate structure in rats. Eur Urol Suppl 2(1):20CrossRef Mitropoulos D, Ploumidou K, Kyroudi-Voulgari A et al (2003) Hypercholesterol diet alters serum lipid profile and ventral prostate structure in rats. Eur Urol Suppl 2(1):20CrossRef
16.
Zurück zum Zitat Vikram A, Jena GB, Ramarao P (2010) Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyper-insulinemia with benign prostate hyperplasia. Prostate 70(1):79–89CrossRefPubMed Vikram A, Jena GB, Ramarao P (2010) Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyper-insulinemia with benign prostate hyperplasia. Prostate 70(1):79–89CrossRefPubMed
17.
Zurück zum Zitat Vignozzi L, Gacci M, Cellai I et al (2013) Fat boosts, while androgen receptor activation counteracts BPH-associated prostate inflammation. Prostate 73(8):789–800CrossRefPubMed Vignozzi L, Gacci M, Cellai I et al (2013) Fat boosts, while androgen receptor activation counteracts BPH-associated prostate inflammation. Prostate 73(8):789–800CrossRefPubMed
18.
Zurück zum Zitat St Sauver JL, Jacobsen SJ, Jacobson DJ et al (2011) Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms. BJU Int 107(3):443–450CrossRefPubMedPubMedCentral St Sauver JL, Jacobsen SJ, Jacobson DJ et al (2011) Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms. BJU Int 107(3):443–450CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Marino G, Pugno E, Cevoli R, Griffa D, Pastorini S, Cocimano V (1991) Pharmacologic treatment of benign prostatic hypertrophy (BPH): a combination of mepartricin and simvastatin. Analysis and results. Minerva Urol Nefrol 43(4):279–282PubMed Marino G, Pugno E, Cevoli R, Griffa D, Pastorini S, Cocimano V (1991) Pharmacologic treatment of benign prostatic hypertrophy (BPH): a combination of mepartricin and simvastatin. Analysis and results. Minerva Urol Nefrol 43(4):279–282PubMed
20.
Zurück zum Zitat Hamilton RJ, Goldberg KC, Platz EA et al (2008) The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 100(21):1511–1518CrossRefPubMed Hamilton RJ, Goldberg KC, Platz EA et al (2008) The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 100(21):1511–1518CrossRefPubMed
21.
Zurück zum Zitat Hall SA, Chiu GR, Link CL et al (2011) Are statin medications associated with lower urinary tract symptoms in men and women? Results from the Boston Area Community Health (BACH) Survey. Ann Epidemiol 21(3):149–155CrossRefPubMedPubMedCentral Hall SA, Chiu GR, Link CL et al (2011) Are statin medications associated with lower urinary tract symptoms in men and women? Results from the Boston Area Community Health (BACH) Survey. Ann Epidemiol 21(3):149–155CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Stamatiou KN, Zaglavira P, Skolarikos A et al (2008) The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride. Int Braz J Urol 34(5):555–561CrossRefPubMed Stamatiou KN, Zaglavira P, Skolarikos A et al (2008) The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride. Int Braz J Urol 34(5):555–561CrossRefPubMed
23.
Zurück zum Zitat Mills IW, Crossland A, Patel A et al (2007) Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement. Eur Urol 52(2):503–509CrossRefPubMed Mills IW, Crossland A, Patel A et al (2007) Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement. Eur Urol 52(2):503–509CrossRefPubMed
24.
Zurück zum Zitat Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, Kratz M, Thompson IM (2010) Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol 171(5):571–582CrossRefPubMedPubMedCentral Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, Kratz M, Thompson IM (2010) Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol 171(5):571–582CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Pace G, Di Massimo C, De Amicis D, Vicentini C, Ciancarelli MG (2011) Inflammation and endothelial activation in benign prostatic hyperplasia and prostate cancer. Int Braz J Urol 37(5):617–622CrossRefPubMed Pace G, Di Massimo C, De Amicis D, Vicentini C, Ciancarelli MG (2011) Inflammation and endothelial activation in benign prostatic hyperplasia and prostate cancer. Int Braz J Urol 37(5):617–622CrossRefPubMed
26.
Zurück zum Zitat Rodríguez-Berriguete G, Prieto A, Fraile B et al (2010) Relationship between IL-6/ERK and NF-κB: a study in normal and pathological human prostate gland. Eur Cytokine Netw 21(4):241–250PubMed Rodríguez-Berriguete G, Prieto A, Fraile B et al (2010) Relationship between IL-6/ERK and NF-κB: a study in normal and pathological human prostate gland. Eur Cytokine Netw 21(4):241–250PubMed
27.
Zurück zum Zitat Fibbi B, Penna G, Morelli A et al (2010) Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 33(3):475–488CrossRefPubMed Fibbi B, Penna G, Morelli A et al (2010) Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 33(3):475–488CrossRefPubMed
28.
Zurück zum Zitat Berthold HK, Berneis K, Mantzoros CS, Krone W, Gouni-Berthold I (2013) Effects of simvastatin and ezetimibe on interleukin-6 and high-sensitivity C-reactive protein. Scand Cardiovasc J Suppl 47(1):20–27CrossRefPubMed Berthold HK, Berneis K, Mantzoros CS, Krone W, Gouni-Berthold I (2013) Effects of simvastatin and ezetimibe on interleukin-6 and high-sensitivity C-reactive protein. Scand Cardiovasc J Suppl 47(1):20–27CrossRefPubMed
Metadaten
Titel
The effects of statins on benign prostatic hyperplasia in elderly patients with metabolic syndrome
verfasst von
Xiangyu Zhang
Xiaofang Zeng
Lini Dong
Xiaokun Zhao
Xiaobing Qu
Publikationsdatum
01.12.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 12/2015
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-015-1550-3

Weitere Artikel der Ausgabe 12/2015

World Journal of Urology 12/2015 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.